Peripherally acting α-adrenoceptor antagonist MK-467 with intramuscular medetomidine and butorphanol in dogs: A prospective, randomised, clinical trial

•The clinical usefulness of MK-467 in healthy dogs sedated with medetomidine–butorphanol for diagnostic imaging was assessed.•A combination of medetomidine, butorphanol and MK-467 provided reliable sedation for short clinical procedures.•Intramuscular MK-467 was associated with increased early stage plasma concentrations of medetomidine and butorphanol.•Increased plasma concentrations of medetomidine–butorphanol were associated with earlier onset deeper initial sedation.